Revvity, Inc. (RVTY)
Instrumentos de laboratorio y diagnóstico in vitro
Revvity combines capital instruments with recurring reagents and consumables in Life Sciences and Diagnostics, with real switching costs and regulatory barriers, but a return on invested capital of just ~3.4% —weighed down by goodwill from historical acquisitions such as BioLegend and Euroimmun— and a stock already trading near its 52-week high after the second-quarter 2026 guidance raise: Preserves value at +3% of 5-year total return, with little margin of safety at the current price.
- Price
- $124.67
- Intrinsic value (5y, base)
- $143
- Total annual return (5y)
- 3.0%
- Status (nominal)
- Preserves value
- Margin of safety
- No margin
The essentials
- Installed-instrument-plus-recurring-consumable model in Life Sciences and Diagnostics, with real switching costs in the laboratory workflow.
- Return on invested capital (~3.4%) sits well below the 10% bar, weighed down by goodwill from historical acquisitions (BioLegend, Euroimmun), not by weak current operations.
- The agreed divestiture of the China Immunodiagnostics business (~6% of FY2025 revenue) simplifies the portfolio; closing is not expected until late 2027.
- Preserves value at +3% of 5-year total return: the stock trades near its 52-week high after the second-quarter 2026 guidance raise, with No margin of safety: at this price capital is preserved, but it is not bought below its value..
Intrinsic value — two valuation methods
Total return at 5 years: 3.0%/year = 2.8% appreciation + 0.2% dividend. The target price ($143) is ex-dividend; the $1 in dividends collected over 5 years are added separately.
The methods disagree: one places the value today above the price ($125) and the other below.
Pillars of the analysis
The verdict — today vs 5 years
Today — expensive, no margin of safety: at $125 trades ~7.5% above its value discounted to today (~$116); the expected return does not even reach the risk-free rate (4.5%).
At 5 years — Preserva valor: the target price ($143) plus dividends yield just enough to preserve nominal capital, below the required 4% floor.
The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$72.
Thesis
The business
Revvity is a laboratory instruments and in vitro diagnostics business with recurring revenue from reagents and consumables, real switching costs, and regulatory barriers (FDA, IVDR) in Diagnostics. The quality of the business is genuine, but return on invested capital (~3.4%) sits well below the 10% bar, weighed down by goodwill from historical acquisitions —not by weak current operations— and the moat is narrow in a fragmented, competitive market.
The valuation
Valued as a single operating business on adjusted earnings (P/E), with a 5-year exit multiple of 17x within the med-tech band [16-22x], in the lower half due to the below-bar return on capital and the narrow moat. That gives a 5-year value of $143 per share versus the current price of $125, for a total return (appreciation plus dividend) of +3% annually.
The margin of safety
No margin of safety: at this price capital is preserved, but it is not bought below its value.. The stock trades at ~22-23x trailing-twelve-month adjusted earnings, in the upper part of the med-tech band, and near its 52-week high after the August 4, 2026 guidance raise: the price already reflects much of the recent momentum in Diagnostics.
What to watch
The key disconfirming test is whether the return on invested capital is structural or transitory: nearly all of the invested capital is goodwill and intangibles from past acquisitions, so organic growth that fails to sustain the current pace would expose the stock to further multiple compression, rather than the moderate expansion of the favorable scenario. Also watch execution of the pending China IDX divestiture (closing not expected until late 2027) and the pharmaceutical/biotech research funding cycle.
Educational / informational. Does not constitute investment advice.